U.S. government taps GlaxoSmithKline for new antibiotics

LONDON (Reuters) – The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats of drug resistance and bioterrorism. The collaboration, the first of its kind between Washington and a drug company, will allow funding to move around GSK's antibiotics portfolio rather than focusing on a single drug candidate. …